However, monoclonal antibodies to VEGF-A, which inhibit angiogenesis, have failed to improve overall survival of patients with newly diagnosed glioblastoma [42, 43] or progressive glioblastomas [44]. The gene discussed is VEGFA; the disease is glioblastoma.